摘要
目的了解目前基本药物独家品种集中采购的现状及存在的问题,并基于该调查提出相关建议。方法在收集整理部分省份基本药物独家品种集中采购政策、中标及价格情况的基础上,进一步对出现的问题进行深入的分析探讨,并针对性的提出建议。结果与结论独家品种的中标率有待提高,中标价格下降幅度较小且在全国范围内保持相对稳定,建议基本药物中的独家品种可采用统一定价、在全国层面上与厂商谈判及各省采购信息共享等采购方式。
Objective To propose reasonable suggestions base on the understanding of the present situation and existing problems in the centralized procurement of exclusive varieties of essential medicine. Methods The centralized procurement policies, bidding information and the purchase prices of several provinces were collected and analyzed, and then reasonable proposals were made. Results and Conclusion The purchase price is relatively stable, but the percentage of winning the bidding should be improved. It is recommended that uniform pricing can be taken for the exclusive varieties＇ centralized procurement, and negotiate with the manufacturers in country-level or sharing the procurement information with other provinces can also be considered.
出处
《中国药事》
CAS
2013年第2期128-131,共4页
Chinese Pharmaceutical Affairs
关键词
基本药物
独家品种
集中采购
统一定价
essential medicine
exclusive varieties
central purchasing
uniform pricing
